The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Trial of Gilead’s Potential Coronavirus Treatment Running Ahead of Schedule

Trial of Gilead’s Potential Coronavirus Treatment Running Ahead of Schedule

April 27, 2020 • By Deena Beasley

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—A key U.S. government trial of Gilead Sciences Inc.’s experimental coronavirus treatment may yield results as early as mid-May, according to the study’s lead investigator, after doctors clamored to enroll their patients in the study.

You Might Also Like
  • Sanofi, Regeneron Expand Testing of Potential Coronavirus Treatment
  • Regeneron Plans Early Summer Trials for New Antibodies Against Coronavirus
  • Sanofi Can Produce Millions of Doses of HCQ, Potential Coronavirus Drug

Preliminary findings from the randomized trial of the antiviral drug remdesivir, begun in February by the National Institute of Allergy and Infectious Diseases (NIAID), could come even sooner, lead researcher Dr. Andre Kalil told Reuters in an interview.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

There are currently no approved treatments or vaccines for COVID-19, the respiratory illness caused by the new virus that has killed over 190,000 people globally, according to a Reuters tally.

Remdesivir has drawn tremendous attention as a therapy with the potential to alter the course of the disease, based on anecdotal reports that it may have helped some patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Those hopes were dampened somewhat on Thursday, when details from a Chinese remdesivir trial in patients with severe COVID-19 inadvertently released by the World Health Organization suggested it provided no benefit.

Gilead pushed back on that interpretation saying the study, which was stopped early due to low patient enrollment, cannot provide meaningful conclusions.

Other reports have provided reason for optimism.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Doctors at Houston Methodist Hospital told Reuters that since March 23, they have treated 41 mostly severely ill COVID-19 patients with the drug. None have died and half are back home.

But they and other doctors contacted by Reuters said they need much more information than the few details available from the Chinese trial and anecdotal reports on its emergency use in the United States to form a view on remdesivir.

They emphasized a need to see how patients on remdesivir fare compared to those who do not receive the therapy in a rigorous clinical trial at different stages of illness to know whether and under what circumstances it may provide benefit.

The NIAID trial “has all the necessary scientific standards that are really going to help us define if this drug works or not,” says Dr. Kalil, a professor at the University of Nebraska Medical Center.

It is a randomized, double-blind study in which half the patients were given the drug and the other half a placebo. Enrollment in the trial closed on Sunday, but has far exceeded initial goals of 400 to 500 patients, he said.

The investigator would not disclose total enrollment, but the latest public update says trial size may exceed 800 patients.

The NIAID trial is designed to show whether remdesivir, when given to patients with a range of disease severity, improves outcomes such as length of hospitalization, need for mechanical ventilation and survival. Dr. Kalil declined to comment on precisely how much of an improvement on those metrics is needed to deem the trial a success and the drug a viable treatment.

Pages: 1 2 3 | Single Page

Filed Under: Drug Updates Tagged With: coronavirus, COVID-19, Gilead, remdesivir

You Might Also Like:
  • Sanofi, Regeneron Expand Testing of Potential Coronavirus Treatment
  • Regeneron Plans Early Summer Trials for New Antibodies Against Coronavirus
  • Sanofi Can Produce Millions of Doses of HCQ, Potential Coronavirus Drug
  • Sanofi, Regeneron Begin Testing Arthritis Drug as Coronavirus Treatment

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.